Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$276.06 USD
+1.03 (0.37%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $276.06 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$276.06 USD
+1.03 (0.37%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $276.06 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth F Momentum F VGM
Zacks News
Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Alnylam Pharmaceuticals (ALNY) and Corcept Therapeutics (CORT) have performed compared to their sector so far this year.
Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QQQJ
Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More
by Zacks Equity Research
Novavax and Alnylam are in the spotlight following drug approval and regulatory updates, respectively.
ALNY Down Despite Positive Data From Heart Disease Drug Study
by Zacks Equity Research
Alnylam presents detailed data from the HELIOS-B study, seeking to expand Amvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy.
Novartis' Cholesterol Drug Meets Primary Goals in Late-Stage Study
by Zacks Equity Research
NVS' late-stage study meets its primary endpoints, demonstrating the superiority of Leqvio monotherapy over both placebo and ezetimibe in LDL-C reduction.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition
by Zacks Equity Research
Alnylam's (ALNY) Amvuttra and Givlaari sales continue to boost revenues. However, its reliance on collaboration partners and stiff competition remain concerns.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal
by Zacks Equity Research
Agios' (AGIO) second-quarter 2024 numbers miss estimates. Its sole-marketed drug fails to meet the primary endpoint of a late-stage label expansion study in pediatric patients with PK deficiency.
Alnylam (ALNY) Up as Q2 Earnings Beat on Collaboration Revenues
by Zacks Equity Research
Alnylam (ALNY) gains 13% on upbeat second-quarter results, beating both earnings and revenue estimates, primarily driven by higher collaboration revenues from Regeneron and strong Amvuttra sales.
Alnylam (ALNY) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alnylam (ALNY) delivered earnings and revenue surprises of 175.68% and 47.14%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Seeking Clues to Alnylam (ALNY) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Alnylam (ALNY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
CRISPR Therapeutics (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) and Alimera Sciences, Inc. (ALIM) are in the spotlight following study and merger updates, respectively.
Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals
by Zacks Equity Research
Alnylam (ALNY) soars as its phase III study, seeking to expand Anvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy, achieves primary and all secondary endpoints.
Company News for Jun 25, 2024
by Zacks Equity Research
Companies In The News Are: RXO, UPS, LLY, ALNY, META, AAPL.
Alnylam (ALNY) Soars 5.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
by Zacks Equity Research
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alnylam (ALNY) delivered earnings and revenue surprises of 78.67% and 17.39%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Annexon (ANNX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Annexon (ANNX) is expected to provide updates from the phase III study evaluating its lead candidate, ANX005, for the treatment of GBS in the first-quarter earnings release.
Gear Up for Alnylam (ALNY) Q1 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.